Methods and kits for predicting esophageal cancer response to anti-ERBB3 antibody treatment

摘要

The present invention is a method for predicting whether esophageal cancer is susceptible or resistant to treatment with an ERBB3 inhibitor (eg, an anti-ERBB3 antibody), and specifically, SDC, PTGES, NCF2, NOXA1. Disclosed is a method of predicting by measuring the expression of RNA level or protein level in a tumor sample of at least one marker selected from CARD6, CARD6 and GNAZ. [Selection diagram] Fig. 12